February 16, 2007Expert Opinion on Investigational Drugs
Beyond heparin and warfarin: the new generation of anticoagulants
Key result
This review outlines the limitations of traditional anticoagulants like heparin and warfarin and highlights the properties, clinical trial results, and potential of new target-specific anticoagulants.
Population
Patients requiring prevention and treatment of venous and arterial thromboembolism
Comparison
New generation of anticoagulants vs Existing anticoagulants (heparin and warfarin)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May guide anticoagulant selection amid traditional agent limitations; leaves open need for definitive randomized outcome trials.
Structured PICO
P
Population
Patients requiring prevention and treatment of venous and arterial thromboembolism
I
Intervention
New generation of anticoagulants (target-specific coagulation enzyme inhibitors that have at least completed Phase II evaluation)
C
Comparator
Existing anticoagulants (heparin and warfarin)
This review highlights the development, properties, and clinical trial results of new target-specific anticoagulants designed to overcome the limitations of heparin and warfarin.
Cite This Study
Weitz et al. (2007) conducted a review in Venous and arterial thromboembolism. New anticoagulants vs. Heparin and warfarin was evaluated. This review outlines the limitations of traditional anticoagulants like heparin and warfarin and highlights the properties, clinical trial results, and potential of new target-specific anticoagulants.